Recipharm and Synthonics join forces to promote novel drug delivery technology

Pharma customers set to benefit from proprietary metal coordination chemistry

Recipharm signs its first joint promotion agreement with Synthonics

Swedish contract development and manufacturing organisation Recipharm Pharmaceutical Development is to work with Synthonics to promote a novel drug delivery technology.

The joint promotion agreement, the first of its kind to be entered into between the two companies, will provide Recipharm customers with access to Synthonics’ metal coordination chemistry, improving the delivery and performance of their compounds.

‘We are pleased to partner Synthonics to expand the services and solutions that we can offer our clients,’ said Maria Lundberg, General Manager of Recipharm Pharmaceutical Development. ‘The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products.’

Ken Slepicka, CEO of US firm Synthonics, added that the company’s chemistry would fit well in Recipharm’s toolkit of solutions.

‘We expect this agreement to help us reach new clients and to expand the use of our chemistry,’ he said.

Companies